Canada - English - Health Canada

hoffmann-la roche limited - peginterferon alfa-2a; ribavirin - solution - 180mcg; 200mg - peginterferon alfa-2a 180mcg; ribavirin 200mg - interferons

Canada - English - Health Canada

hoffmann-la roche limited - peginterferon alfa-2a; ribavirin - solution - 180mcg; 200mg - peginterferon alfa-2a 180mcg; ribavirin 200mg - interferons

Canada - English - Health Canada

pharmaand gmbh - peginterferon alfa-2a - solution - 180mcg - peginterferon alfa-2a 180mcg - interferons

Canada - English - Health Canada

hoffmann-la roche limited - peginterferon alfa-2a - solution - 180mcg - peginterferon alfa-2a 180mcg - interferons

United States - English - NLM (National Library of Medicine)

biogen inc. - peginterferon beta-1a (unii: i8309403r0) (peginterferon beta-1a - unii:i8309403r0) - peginterferon beta-1a 94 ug in 0.5 ml - plegridy is indicated for the treatment of relapsing forms of multiple sclerosis (ms), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. plegridy is contraindicated in patients with a history of hypersensitivity to natural or recombinant interferon beta or peginterferon, or any other component of plegridy [see warnings and precautions ( 5.3)] . risk summary data from a large population-based cohort study, as well as other published studies over several decades, have not identified a drug-associated risk of major birth defects with the use of interferon beta products during early pregnancy. findings regarding a potential risk for low birth weight or miscarriage with the use of interferon beta products in pregnancy have been inconsistent (see data). in a study in pregnant monkeys, administration of interferon beta during pregnancy resulted in an increased rate of abortion (see data ). in the u.s. general population, the estimated backgro

European Union - English - EMA (European Medicines Agency)

biopartners gmbh - ribavirin - hepatitis c, chronic - antivirals for systemic use - ribavirin biopartners is indicated for the treatment of chronic hepatitis-c-virus (hcv) infection in adults, children three years of age and older and adolescents and must only be used as part of a combination regimen with interferon alfa-2b. ribavirin monotherapy must not be used. there is no safety or efficacy information on the use of ribavirin with other forms of interferon (i.e. not alfa-2b).naïve patientsadult patientsribavirin biopartners is indicated, in combination with interferon alfa-2b, for the treatment of adult patients with all types of chronic hepatitis c except genotype 1, not previously treated, without liver decompensation, with elevated alanine aminotransferase (alt), who are positive for hepatitis c viral ribonucleic acid (hcv-rna) (see section 4.4)children three years of age and older and adolescentsribavirin biopartners is intended for use, in a combination regimen with interferon alfa-2b, for the treatment of children three years of age and older and adolescents, who have all types of chronic hepatitis c except genotype 1, not previously treated, without liver decompensation, and who are positive for hcv-rna.when deciding to not to defer treatment until adulthood, it is important to consider that the combination therapy induced a growth inhibition. the reversibility of growth inhibition is uncertain. the decision to treat should be made on a case by case basis (see section 4.4).previous-treatment-failure patientsadult patientsribavirin biopartners is indicated, in combination with interferon alfa-2b, for the treatment of adult patients with chronic hepatitis c who have previously responded (with normalisation of alt at the end of treatment) to interferon alfa monotherapy but who have subsequently relapsed (see section 5.1).

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

merck sharp & dohme ltd - interferon alfa-2b - solution for injection - 25mega u/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

merck sharp & dohme ltd - interferon alfa-2b - solution for injection - 15mega u/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

merck sharp & dohme ltd - interferon alfa-2b - powder and solvent for solution for injection - 10mega u

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

merck sharp & dohme ltd - interferon alfa-2b - solution for injection - 50mega u/1ml